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Abstract 
Aims: To compare weight change in a lifestyle-based weight management programme 
between participants taking weight-gaining, weight-neutral/loss and mixed diabetes 
medications.  
Methods: Electronic health records for individuals (≥18 years) with type 2 diabetes who had 
been referred to a non-surgical weight management programme between February 2008 and 
May 2014 were studied. Diabetes medications were classified into three categories based on 
their effect on body weight. In this intervention cohort study, weight change was calculated 
for participants attending ≥2 sessions.  
Results: All 998 individuals who took oral diabetes medications and attended ≥2 sessions of 
weight management were included. 59.5% were women with a mean BMI of 41.1 kg/m
2
 
(women) and 40.2 kg/m
2 
(men). Of the diabetes medication combinations prescribed, 46.0% 
were weight-neutral/loss, 41.3% mixed and 12.7% weight-gaining. The mean weight change 
for participants on weight-gaining and weight-neutral/loss diabetes medications respectively 
was -2.5 kg (95% CI: -3.2 to -1.8 kg) and -3.3 kg (95% CI: -3.8 to -2.9 kg) (p = 0.05) for 
those attending ≥2 sessions (n = 998). Compared to those prescribed weight neutral 
medications, those prescribed weight gaining medication lost 0.86kg less (95% CI: 0.02 to 1.7 
kg; p=0.045) in a model adjusted for age, sex, BMI and socioeconomic status. 
Conclusions: Participants on weight-neutral/loss diabetes medications had a greater absolute 
weight loss within a weight management intervention compared with those on weight-gaining 
medications. Diabetes medications should be reviewed ahead of planned weight-loss 
interventions to help ensure maximal effectiveness of the intervention. 
 
 
Keywords 
Weight control, type 2 diabetes, observational study, database research, obesity 
therapy. 
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What's new? 
- In many oral diabetes medications are associated with weight gain, which makes 
the management of type 2 diabetes in individuals with overweight and obesity 
more challenging. 
- There was a clinically significant larger weight loss in individuals on weight-neutral/ loss 
diabetes medication compared to those on weight-gaining medication. 
- There is a gradated relationship between greater use of weight-gaining diabetes 
medication and lower success of a weight-loss programme. 
- Diabetes medication regimens should be reviewed prior to referral to a weight 
management programme to ensure that, when possible, weight neutral/ loss medications 
are used preferentially over weight-gaining medications.  
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Introduction 
 
Obesity is the major risk factor for the development type 2 diabetes mellitus (Type 2 DM) and 
87.2% of people living with Type 2 DM have a body mass index (BMI) in the overweight or 
obese range [1]. Weight gain and obesity increases the likelihood of developing Type 2 DM
 
[2], therefore weight loss is a key therapeutic goal in the management of Type 2 DM [3]. 
National Institute of Clinical Excellence (NICE)
 
[4] and the American Diabetes Association 
(ADA) guidelines [5] recommend that people with obesity and Type 2 DM should have 
individualised interventions, including behavioural interventions, pharmacotherapy or surgery 
to promote weight loss, in order to improve glycaemic control. However there is no guidance 
given on how to manage the treatment of Type 2 DM around the time of a weight 
management programme. 
 
Many diabetes medications are associated with weight gain [6]. Therefore, the ADA and the 
European Society for the Study of Diabetes (EASD) have developed an algorithm for 
hyperglycaemia management in Type 2 DM where individuals who have a BMI in the 
overweight or obese range should be initially prescribed diabetes medication that either 
contributes to weight reduction or does not have an effect on weight [3].
 
They recommend 
that metformin be used first-line for people with Type 2 DM with a body mass within the 
normal, overweight or obese range. If metformin proves inefficient in regulating glycaemia, 
or is contraindicated for individuals with overweight or obesity, then glucagon-like peptide-
1(GLP-1 receptor) agonists, sodium-glucose co-transporter-2 (SGLT2) inhibitors, and 
dipeptidylpeptidase-4 (DPP-4) inhibitors should be considered as these are associated with 
weight reduction [3]. 
 
Sulfonylureas and thiazolidinediones are known to cause weight gain. The United Kingdom 
Prospective Diabetes Study (UKPDS) suggests that sulfonylureas can cause 5kg weight gain 
over a 10-year period of treatment [7].
 
In addition, in the PROACTIVE trial, the 
thiazolidinediones pioglitazone produced an average of 3.6 kg weight gain over three years 
[8]. Conversely, 27 randomised controlled trials (RCTs) show that GLP-1 receptor agonists 
were associated with significant weight reduction and a mean weight loss of -1.74 kg
 
[9]. A 
significant reduction in body weight was recorded in a 52-week study, in which the SGLT2 
inhibitor empagliflozin was added to insulin treatment for people who have obesity with 
uncontrolled diabetes [10]. 
 
 
  
5 
 
While some diabetes medications can lead to weight gain, there is currently no evidence as to 
the effect of these same medications on the ability of an individual to intentionally lose 
weight within a weight management programme. There is evidence that those with Type 2 
DM achieve lower weight loss within these programmes than those without diabetes, and 
medications have been suggested as a contributory factor [11]. There have been no studies 
examining the outcomes of weight management by diabetes medication class. The aim and 
novelty of this study is to compare weight changes in a lifestyle-based weight management 
programme between participants taking weight-gaining, weight-neutral and mixed diabetes 
medications. 
 
Methods 
Study procedure 
This study uses data from electronic health records from the Glasgow and Clyde Weight 
Management Service (GCWMS), based in Glasgow, United Kingdom. The service is part of 
the National Health Service and is accessible to people aged 18 years and over with complex 
obesity (defined as BMI ≥30 kg/m
2
 with obesity-related comorbidities, or BMI ≥35 kg/m
2
), 
who have been referred by a GP or hospital doctor. The goal of the service is to support 
people to achieve weight losses of at least 5 kg.  
 
The GCWMS intervention studied here, predominately delivered in group settings, consists of 
diet (600 kcal deficit diet), exercise and behavioural advice over nine sessions (90 min), 
delivered once every two weeks over a 16-week period. Personalised dietary prescriptions are 
calculated based on the participant's age and sex. Sessions involve semi-structured dietician 
led presentations and group discussion to encourage lifestyle change and healthy eating based 
on the Eatwell Plate [12]
 
and behaviour change approaches. Supplementary exercise sessions 
(weekly group based; physiotherapy led), psychological talks/seminars (self-help advice), and 
more intensive 1:1 or group psychological therapy may be offered. 
 
Diabetes medication classification 
Diabetes medications were classified into seven groups: biguanides, DPP-4 inhibitors, GLP-1 
receptor agonists, SGLT2 inhibitors, thiazolidinediones, sulfonylureas and insulin. Brand 
names in addition to any combined medications available in the UK were identified using the 
British National Formulary (BNF) 2016 [13]. Using data from RCTs
 
[9, 14, 15, 16], the 
medications were then categorised according to their effect on body weight (combination 
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medications were categorised by their individual components) as weight-neutral/loss, or 
weight-gaining. Three groups were formed: 
 
1. Weight neutral/loss medications: 
Metformin only or Metformin +DPP-4 +/OR GLP-1 +/OR SGLT2 
 
2. Mixed weight effect medications: 
(Sulfonylureas) AND (Metformin +/OR DPP-4 +/OR GLP-1 +/OR SGLT2)  
or (Thiazolidinediones + sulfonylureas) OR (TZDs) AND (Metformin +/OR DPP-4 +/OR 
GLP-1 +/OR SGLT2) 
 
3. Weight gaining medications: 
 Sulfonylureas only or sulfonylureas + thiazolidinediones or any combination including 
insulin 
 
Data source, inclusion and exclusion criteria 
At referral, all medications were imported into the GCWMS database from the Scottish Care 
Information (SCI) gateway referral. This is an electronic referral system that transmits 
prescription information from the general practice IT system. Current prescriptions at time of 
participant’s referral were evaluated. Search terms were used to ascertain the diabetes 
medications used for classification and coding according to the BNF [13]. Participants aged 
≥18 years, referred to GCWMS between 1/1/2008 and 31/12/2014, prescribed diabetes 
medications and attending ≥2 sessions in the lifestyle phase were included. If the same person 
was referred more than once, information from the earliest referral only was included [17, 
18]. Type 2 diabetes status was determined from either mention on the primary care referral 
form or at assessment visit. Each person was assigned to one category of medication as 
described above, and any person on insulin only or on any combination not described above 
was excluded. Initial numbers in each drug group, mean BMI, BMI categories, sex, the 
Scottish Index of Multiple Deprivation (SIMD) and age were identified. The SIMD score is 
calculated from information on seven domains (current income, employment, health, 
education, skills and training, geographic access to services, housing, and crime) to describe 
the level of deprivation in small geographic areas (6,505 data zones) across Scotland. The 
SIMD is used to derive quintiles of socioeconomic status for the Scottish population, ranging 
from 1 (most deprived) to 5 (least deprived). Prior to analysis, programme completion was 
defined as completion of the programme with attendance at 80% of the sessions; i.e. ≥seven 
sessions attended out of a possible nine. This analysis was conducted by employees of the 
Health Board as part of a wider service evaluation using an anonymised dataset. All 
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participants had given written consent for the use of their data for service evaluation and 
research purposes, and written permission for this analysis was granted by the GCWMS 
Operational Research Committee. 
 
Statistical methods 
The results are reported as number, mean and percentages. The differences in participant 
characteristics, such as mean age and BMI, were tested using an independent samples t-test. A 
Chi-square test for trend was used to test differences in ordinal variables. Differences in mean 
weight change and mean percentage weight change were analysed using two-way t-test 
(between two groups) and ANOVA (more than two groups) for continuous data. The 
Bonferroni (pairwise) test was used to adjust for multiple comparisons. Statistical significance 
was defined as p <0.01 in the case of multiple comparisons, and p <0.05 up to two pair 
comparisons. All statistical analyses were performed using Stata version 12.1 (StataCorp, 
College Station, Texas). A stratified analysis was also conducted to allow visualisation of the 
potential confounding factors. Finally, to minimise the effect of potential confounding factors, 
such as initial BMI, sex and age, a multivariable regression was conducted adjust for age, sex, 
baseline BMI group and SIMD.  
 
Results 
 
Baseline characteristics 
In total, 998 individuals with Type 2 DM attended ≥2 sessions of weight management at 
GCWMS and 560 completed the programme (59.5% women). 46.0%, 41.3% and 12.7% of 
those included were on weight-neutral/loss, mixed and weight-gaining diabetes medications 
respectively. Compared to those prescribed weight-gaining medications, those prescribed 
weight-neutral medications had a higher mean BMI (BMI 42.3 kg/m
2
 [95% CI: 41.6 to 43.0 
kg/m
2
] vs 40.8 kg/m
2
 [95% CI: 39.7 to 42.0 kg/m
2
]; p = 0.037) and were younger (mean ages 
were 52.1 years [95% CI: 51.0 to 53.3 years] and 58.2 years [95% CI: 56.3 to 60.2 years], 
respectively; p = 0.001). 
 
Table 1 shows the baseline characteristics of the included population by medication group. A 
lower proportion (9.8%) of individuals with higher BMIs were prescribed weight-gaining 
medications (p = 0.19). Additionally, a higher proportion of older people (≥50 years) were 
prescribed weight-gaining medications, than younger people (p = 0.001). Moreover, a higher 
proportion of women were prescribed weight-neutral/loss medications (50.0%) than men 
(40.1%) (p = 0.002). There was no association between SIMD and medication prescribing (p 
= 0.08, 0.34 and 0.41). 
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Weight loss outcomes 
There is a gradated relationship between greater use of weight-gaining diabetes medication 
and lower success of a weight-loss programme. By the end of the lifestyle programme (16 
weeks), participants prescribed weight-neutral/loss medications (n=248) who completed the 
programme had a greater absolute weight loss than those prescribed weight-gaining 
medications (n=76); mean weight changes were -4.9 kg (95% CI: -5.5 to -4.2 kg) and -3.3 kg 
(95% CI: -4.2 to -2.5 kg, p = 0.005), respectively (Table 2, Figure 1). The difference in 
percentage weight change between the two groups (-4.1% [95% CI: -4.6 to -3.6%] vs -3.2% 
[95% CI: -4.0 to -2.4%]) did not reach statistical significance (p = 0.06). The mean weight 
change for patients on mixed medications who completed the programme was -4.3 kg (95% 
CI: -4.8 to -3.8 kg). Accounting for the total group, including those who did not complete the 
programme, weight loss was -3.3 kg (95% CI: -3.8 to -2.9 kg) in the weight-neutral/loss 
medication group and -2.5 kg (95% CI: -3.2 to -1.8 kg) in the weight-gaining medication 
group (p = 0.05). 
There were no significant differences between the participants, neither completers nor the 
whole cohort, prescribed weight-neutral/loss medications and those prescribed mixed drugs in 
terms of mean change in weight or percentage of weight loss (p = 0.73 and 0.98, 
respectively). However, the difference in weight change among completers was between the 
weight-neutral/loss and weight-gaining groups (p=0.005) and suggests a gradated 
relationship.  
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Weight loss outcomes by baseline characteristics 
To explore if the effect of differences in baseline characteristics between groups a stratified 
analysis (Table 3) and multivariate regression (supp table 1) was conducted. The mean weight 
change when prescribed weight-neutral/loss medications was -3.93 kg (95% CI: -4.7 to -3.0 
kg) for men and -2.98 kg (95% CI: -3.4 to -2.5 kg) for women, (p = 0.02 for difference 
between sexes) (Table 3). Men made up a higher proportion of the group prescribed mixed 
medications (45.4%), and women made up a higher proportion of those prescribed weight 
neutral/loss medications (64.6%). There was no significant weight change between men and 
women prescribed mixed-effects medications (mean change in men and women was -3.32 kg 
(95% CI: -3.8 to -2.8 kg) and -3.12 kg (95% CI: -3.6 to -2.5 kg), p = 0.59, respectively). 
There was no difference in the mean weight loss between men and women prescribed weight-
gaining medications (p = 0.98). Weight loss among those prescribed weight-neutral/loss, 
mixed or weight-gaining diabetes medications did not vary by BMI, age, or socio-economic 
deprivation category (SIMD) (all p>0.05). Examining the total cohort (those attending  2 
sessions; n=998), there was 0.86kg less weight loss (95% CI: 0.02 to 1.7 kg; p = 0.045) in 
those prescribed weight gaining medications compared to those on weight neutral/ loss 
medications, in a model adjusted for age, sex, BMI group and socio-economic deprivation 
category (SIMD). 
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Discussion 
Among all participants prescribed diabetes medications, we found that a lifestyle-based 
weight loss programme was less effective for people prescribed weight-gaining medications. 
The objective of this research was to study the relationship between prescribed diabetes 
medications and subsequent weight loss within a weight management intervention. Weight 
loss is essential for diabetes management as glycaemic control and cardiovascular risk factors 
improve with 5-10%
 
weight loss [19]. Despite it being well known that diabetes medications 
can affect body weight, this is the only study to our knowledge to report the effects of these 
medications on intentional weight loss outcomes, an area of increasing interest in the 
treatment of Type 2 DM [20]. Participants who were prescribed weight-gaining diabetes 
medications lost less weight than those on weight-neutral/loss medications, with a 0.86 kg 
difference between groups in a model adjusting for potential confounding factors. This 
difference is clinically significant in the context of weight management for reducing the risk 
of complications. 
 
46.0%, 41.3% and 12.7% of the included participants were on weight-neutral/loss, mixed and 
weight-gaining diabetes medication respectively. This is consistent with DiaRegis cohort 
study, a real-world study of 3,807 people with Type 2 DM  in Germany, which found that 
people with lower BMI were more likely to be prescribed SUs or insulin, while people with 
higher BMI were more likely to be prescribed biguanides or GLP-1 receptor agonists [21]. 
We found that weight-neutral/loss medications were prescribed more frequently for younger 
people, consistent with a previous study by Ewenighi et al
 
[22], which found that only age 
and initial BMI influenced the prescribing of diabetes medications. 
 
There was a difference in mean weight loss between men and women who were prescribed 
weight-neutral/loss medications, however a lower proportion of men were prescribed weight-
neutral medications compared to other medications. However, men who were prescribed 
weight-neutral medications lost the largest amount of weight meaning the relationship 
between medication type and weight loss was not wholly confounded by sex. A previous 26-
week RCT compared the effect of liraglutide or rosiglitazone with glimepiride on weight 
change and glycaemic control in 1,041 participants. It reported that sex does not influence the 
effect of liraglutide on weight change, which is consistent with the current results [23]. In 
addition, in a two-year follow up of the DiaRegis cohort study, Hartmann et al. found that the 
association between diabetes medications and weight change was not influenced by the sex or 
age of participant [21]. 
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The difference in weight loss achieved across the three medication groups was in keeping 
with the known effects of these medications on body weight, when prescribed without the 
addition of a lifestyle weight management intervention. For instance, an earlier study (1-year 
duration) of 639 individuals with Type 2 DM showed that participants who received 
sulfonylureas plus thiazolidinediones gained an average of 2.8 kg, compared with a reduction 
of 1 kg in those prescribed metformin plus sulfonylureas [24]. In addition, a four-year 
randomised study of 4,360 participants with Type 2 DM uncontrolled by lifestyle intervention 
and treated with metformin, rosiglitazone or glibenclamide showed individuals in the 
metformin group lost weight, with weight gain in the glibenclamide and rosiglitazone groups; 
this difference was greatest between the metformin and the rosiglitazone group [25]. 
Moreover, a retrospective study (1-year duration) of 2,641 participants reported that people 
on metformin had lost an average weight of -2.6 kg (95% CI: -2.5 to -2.9 kg), and those on 
sulfonylureas had gained 0.3 kg (95% CI: -0.2 to 0.8 kg) [26]. 
 
The beneficial effects of weight loss on glycaemic control and minimizing the number of 
diabetes medications used by people with diabetes are now established
 
[27, 28], as are the 
weight gaining effects of commonly used diabetes medications. Failure to lose weight early 
within a weight management intervention is associated with nonattendance and 
disengagement
 
[29], leading to poor weight loss outcomes. It is therefore vital that a review of 
person’s medications is conducted before commencing a weight management intervention 
and where possible prescribing people with alternative medications that are not associated 
with weight gain without compromising glycaemic control. 
 
Strengths and limitations 
The main strength of this research is the unique large dataset available, derived from one of 
the largest weight management programmes in the United Kingdom, providing objective 
measures of weight and height. The gradated relationship, showing intermediate weight 
changes among participants prescribed mixed-effect medications, strengthens the observation 
that the relationship may be causal. To the best of our knowledge, this is the only study to 
observe the association between diabetes medications and weight change for individuals with 
obesity and Type 2 DM (the included participants had a BMI of ≥30 kg/m
2
).
 
There was 
potential prescribing bias due to people being prescribed their medication based on age and 
weight. Selection bias was minimal, with only 1.8% of participants excluded (on account of 
their being on drug regimens that could not be classified into one of the groups). The 
prescribing information is likely to be accurate, as all data were sourced from electronic 
prescription records. The main weakness of this study was the lack of comorbidity 
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information, the lack of information on the participants’ duration of Type 2 DM and how long 
they had been prescribed the medications, which may have influenced their effect; however 
duration and age are likely closely related and age did not confound the relationship. In 
addition, it is possible that prescribed the medications may have changed between referral and 
starting the programme, but the likelihood of this is considered low given the short time 
between referral and starting the programme. 
 
Conclusions  
Individuals prescribed weight-neutral/loss diabetes medications had a greater absolute weight 
loss within a weight management intervention compared with those prescribed weight-
gaining medications. While those prescribed weight neutral medications had a higher BMI on 
average than those on weight gaining medications, there were many prescribed weight 
gaining medications that were deemed in need of weight management. Ensuring that people 
are prescribed appropriate diabetes medications at the time of referral to a lifestyle weight 
management programme may help maximise the success of the intervention. Future studies to 
assess the long-term effects of diabetes medications on weight loss maintenance and 
glycaemic control during weight loss will help clarify clinical guidance in this important area.   
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TABLE 1 Baseline characteristics of people referred to GCWMS with Type 2 DM. 
 All 
participants 
included 
(attended ≥2 
session) 
N=998 
Weight-
neutral 
medications 
n=459 (46%) 
 
 
p 
Mixed 
medications 
n=412 
(41.3%) 
 
 
p 
Weight-
gaining 
medications 
n=127 
(12.7%) 
 
 
      p 
 N(% of total 
cohort) 
n(% of total subgroup) 
Sex 
Men 
Women 
Not known 
 
404 (40.5) 
594 (59.5) 
 
162 (40.1) 
297 (50.0) 
 
0.002 
 
187 (46.3) 
225 (37.9) 
 
0.008 
 
55 (13.6) 
72 (12.1) 
 
  0.48 
 
Initial BMI 
(kg/m
2
) 
 
3034.9 
3539.9 
4049.9 
≥50 
 
 
 
 
170 (17.0) 
289 (29.0) 
427 (42.8) 
112 (11.2) 
 
 
 
 
70 (41.2) 
121 (41.9) 
210 (49.2) 
58 (51.8) 
 
 
 
  
0.07 
 
 
 
 
71(41.8) 
129 (44.3) 
169 (39.6) 
43 (38.4) 
 
 
 
 
0.52 
 
 
 
 
29 (17.1) 
39 (13.5) 
48 (11.2) 
    11(9.8) 
 
 
 
 
0.19 
 
Age (years) 
 
1829 
3039 
4049 
5059  
6069 
≥70 
 
 
 
24 (2.4) 
78 (7.8) 
186 (18.6) 
330 (33.1) 
289 (29.0) 
91 (9.1) 
 
 
 
20 (83.3) 
56 (71.8) 
105 (56.5) 
142 (43.0) 
105 (36.3) 
31 (34.1) 
 
 
 
0.001 
 
 
 
2 (8.3) 
16 (20.5) 
64 (34.4) 
149 (45.2) 
136 (47.1) 
45 (49.4) 
 
 
 
0.001 
 
 
      
     2 (8.3) 
     6 (7.7) 
     17(9.1) 
39 (11.8) 
48 (16.6) 
15 (16.5) 
 
 
 
0.08 
 
SIMD 
Most deprived 
2 
3 
4 
Least deprived 
Not known 
 
 
 
  396 (39.7) 
202 (20.2) 
146 (14.6) 
124 (12.4) 
126 (12.6) 
4 (0.4) 
 
 
191 (48.2) 
98 (48.5) 
64 (43.8) 
43 (34.7) 
60 (47.6) 
3 (75.0) 
 
 
0.08 
 
 
157 (39.6) 
78 (38.6) 
60 (41.1) 
61 (49.2) 
55 (43.7) 
1 (25.0) 
 
 
0.34 
 
 
48 (12.1) 
26 (12.9) 
22 (15.1) 
20 (15.9) 
    11(8.7) 
0 
 
 
0.41 
Abbreviations: GCWMS, Glasgow and Clyde Weight Management Services; Type 2 DM, Type 2 
Diabetes Mellitus; BMI, Body Mass Index; SIMD, Scottish Index of Multiple Deprivation; N, number. 
(P-value <0.01 considered statistically significant). 
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TABLE 2 Weight loss outcomes for people with Type 2 DM receiving different categories of diabetes medication.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Abbereviations: N, Number; CI, Confidence Interval. (P-value <0.05 considered statistically significant). The difference in weight change among completers (attended ≥7 
session) was between the weight-neutral/loss and weight-gaining groups (p=0.005). However, there was no difference in case of percentage weight change. 
Drugs categories 
n  
(Total =998) 
% 
Mean weight 
change and 95% 
CI (kg) 
p-value  
( completers ) 
(groups 
compared) 
p-value  
(total) 
(groups 
compared) 
Mean % weight 
change and 95% 
CI 
p-value  
( completers ) 
(groups 
compared) 
p-value  
(total) 
(groups 
compared) 
1- Weight-neutral 
medications 
   
 
 
 
 
 
 
 
 
 
 
1 vs 2 
0.14 
 
 
 
 
 
 
 
 
      1 vs 3 
0.005 
 
 
 
 
 
 
 
 
 
 
1 vs 2 
0.73 
 
 
 
 
 
 
 
 
      1 vs 3 
0.05 
  
 
 
 
 
 
 
 
 
 
1 vs 2 
0.31 
 
 
 
 
 
 
 
 
        1 vs 3 
  0.06 
 
 
 
 
 
 
 
 
 
 
1 vs 2 
0.98 
 
 
 
 
 
 
 
 
   1 vs 3  
     0.17                 
 
 
 
Completers (≥7 
sessions) 
248 54.0 -4.9 (-5.5 to -4.2) -4.1 (-4.6 to -3.6)  
Non-completers (˂7 
sessions) 
211 46.0 -1.4 (-1.8 to -1.0) 
 
Total (≥2 sessions) 459   -3.3 (-3.8 to -2.9) -2.8 (-3.1 to -2.5) 
 
2- Mixed 
medications 
   
 
Completers (≥7 
sessions) 
236 57.2 -4.3 (-4.8 to -3.8) 3.8 (-4.2 to -3.3) 
Non-completers (˂7 
sessions) 
176 42.7 -1.7 (-2.2 to 1.2) 
 
Total (≥2 sessions) 412     -3.2 (-3.5 to -2.8) -2.8 (-3.1 to -2.4) 
 
3- Weight-gaining 
medications 
 
   
 
Completers (≥7 
sessions) 
76 59.8 -3.3 (-4.2 to -2.5) -3.2 (-4.0 to -2.4) 
Non-completers (˂7 
sessions) 
51 40.1 -1.1 (-2.2 to -0.9) 
 
Total (≥2 sessions) 127  -2.5 (-3.2 to -1.8) -2.3 (-2.9 to -1.7) 
 
  
17 
 
TABLE 3 Stratified analysis of weight loss with three different categories of diabetes medications at end of the lifestyle phase in completers and non-
completers. 
Abbreviations: n, number; CI, Confidence Interval, BMI, Body Mass Index; SIMD, Scottish Index of Multiple Deprivation. 
 
 
 
 
  Weight-neutral medications (n = 459)  Mixed medications (n = 412)  Weight-gaining medications (n = 127) 
 
 
Category (n) 
 Mean weight 
change (kg) and 
(95% CI) 
n (%) P Mean weight change (kg)  
and (95% CI) 
n (%) P Mean weight change 
(kg) and (95% CI) 
n (%)             P         
 
 
Men (404) 
Women (594) 
           -3.93 (-4.7 to -3.0) 
-2.98 (-3.4 to -2.5) 
163 (35.5) 
296 (64.5) 
0.02 -3.32 (-3.8 to -2.8) 
          -3.12 (-3.6 to -2.5)               
187 (45.4) 
225 (54.6) 
   0.59 -2.51 (-3.7 to -1.2) 
-2.50 (-3.2 to -1.7)       
55 (43.3) 
72 (56.7) 
0.98  
 
BMI 3034.9 kg/m2 (179) 
BMI 3539.9 kg/m2 (301) 
  
-2.48 (-3.2 to -1.6) 
-2.82 (-3.5 to -2.0) 
1 -3.68 (-4.3 to -3.0) 
 
70 (15.3) 
121 (26.4) 
 
0.08 
 
-2.80 (-3.4 to -2.1) 
-2.83 (-3.3 to -2.3) 
 
71 (17.2) 
129 (31.3) 
 
   0.27 
 
-2.86 (-3.9 to -1.7) 
-2.04 (-3.4 to -0.5) 
 
29 (22.8) 
39 (30.7) 
 
 0.84 
 
 
BMI 4049.9 kg/m2 (414)  210 (45.7)            -3.5 (-4.2 to -2.8) 169 (41.0)  -2.61 (-3.8 to -1.4) 48 (37.8)   
BMI ≥50 kg/m2 (104)  -3.98 (-5.0 to -2.9) 58 (12.6)  -3.70 (-5.3 to -2.0) 43 (10.4)  -2.72 (-4.7 to -0.7) 11 (8.7)   
 
Age 1829 years (24) 
  
-2.01 (-3.6 to -0.3) 
 
20 (4.4) 
  
-1.69 (-4.6 to 1.2) 
 
2 (0.5) 
  
-0.29 (-1.6 to 1.0) 
 
2 (1.6) 
  
 
3039 years (78)  -2.66 (-3.7 to -1.6) 56 (12.2) 0.55   -1.72 (-2.8 to -0.6) 16 (3.9)    0.44 -3.98 (-6.9 to -0.9) 6 (4.7)   0.55  
4049 years (186)  -3.54 (-4.4 to -2.6) 105 (22.9)  -2.79 (-3.5 to -2.0) 64 (15.5)  -2.31 (-3.8 to -0.8) 17 (13.4)   
5059 years (330)  -3.64 (-4.4 to -2.8) 142 (30.9)  -3.13 (-3.7 to -2.4) 149 (36.2)  -2.45 (-3.8 to -1.0) 39 (30.7)   
6069 years (289)  -3.2 (-4.1 to -2.3) 105 (22.9)  -3.48 (-4.1 to -2.8) 136 (33.0)  -3.02 (-4.2 to -1.8) 48 (37.8)   
≥70 years (91)  -3.00 (-4.6 to -1.4) 31 (6.7)  -3.75 (-5.2 to -2.2) 45 (10.9)  -1.20 (-2.7 to 0.3) 15 (11.8)   
 
SIMD: 1 (most deprived) (396) 
 
 
-2.92 (-3.5 to -2.2) 
 
191 (41.9) 
  
-3.04 (-3.6 to -2.4) 
 
157 (38.2) 
 
 
-2.71 (-3.6 to -1.7) 
 
48 (37.8) 
  
 
2 (202)  -3.28 (-4.0 to -2.5) 98 (21.5) 0.39 -2.78 (-3.5 to -1.9) 78 (19.0)    0.45 -1.86 (-3.6 to -0.7) 26 (20.5)    0.15  
3 (146)  -3.85 (-4.9 to -2.7) 64 (14.0)  -3.67 (-5.0 to -2.3) 60 (14.6)  -1.10 (-2.4 to 0.2) 22 (17.3)   
4 (124)  -3.05 (-4.5 to -1.5) 43 (9.4)            -3.1 (-4.0 to -2.2) 61 (14.8)  -3.48 (-5.2 to -1.0) 20 (15.7)   
5 (least deprived) (126)  -4.05 (-5.3 to -2.7) 60 (13.2)  -3.88 (-4.9 to -2.8) 55 (13.4)  -4.14 (-7.2 to -1.0) 11 (8.7)   
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Supplementary table: 
 
SUPPLEMENTARY TABLE 1 Multivariable regression of weight change (kg) with baseline characteristics. 
 
Baseline characteristics Coefficient 95%CI p-value 
Drug group 
neutral 0     
mixed 0.21 (-0.37, 0.79) 0.47 
weight gaining 0.86 (0.02, 1.70) 0.045 
Sex 
women 0 
  
men -0.40 (-0.94, 0.14) 0.14 
Age group 
(years) 
<40 0     
40-49 -0.72 (-1.74, 0.30) 0.17 
50-59 -0.86 (-1.82, 0.10) 0.08 
60-79 -1.09 (-2.08, -0.10) 0.032 
70+ -0.76 (-2.00, 0.47) 0.23 
BMI group 
(kg/m2) 
<35 0 
  
35-<40 -0.35 (-1.13, 0.43) 0.38 
40-<45 -0.55 (-1.36, 0.25) 0.18 
45-<50 -1.06 (-2.00, -0.13) 0.026 
50+ -1.00 (-2.04, 0.05) 0.06 
SIMD quintile 
1 0 
  
2 0.01 (-0.70, 0.73) 0.97 
3 -0.45 (-1.26, 0.35) 0.27 
4 -0.26 (-1.11, 0.60) 0.56 
5 -0.98 (-1.83, -0.12) 0.026 
Constant -1.66 (-2.76, -0.57) 0.00 
     Coefficients represent difference in change in weight (kg) compared to reference category 
+ values indicate less weight loss, - values indicate more weight loss. 
CI, Confidence Interval, BMI, Body Mass Index; SIMD, Scottish Index of Multiple Deprivation. 
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FIGURE 1 The mean weight change (kg) and the 95% confidence intervals (CI) at 
the end of the lifestyle programme for three different diabetes medication categories. 
Total completers, n=560 (≥7 sessions; p = 0.14, between groups 1 and 2; p = 0.005, 
between groups 1 and 3). Total participants including non-completers, n=998 (≥2 
sessions; p = 0.73, between groups 1 and 2; p = 0.05, between groups 1 and 3). 
 
